Business Wire

MobileIron Extends Microsoft Integration with Support for Microsoft Intune Device Compliance Service

Share

MobileIron (NASDAQ:MOBL), the industry’s first mobile-centric, zero trust security platform, announced they have extended their Microsoft Enterprise Mobility + Security (EMS) integration to support Microsoft Intune Device Compliance service for Microsoft 365 and other managed apps. This new solution allows MobileIron’s secure device management capabilities to leverage Microsoft Intune and Azure Active Directory Conditional Access to secure applications such as Office 365.

Customers already using Microsoft 365 or Microsoft Enterprise Mobility + Security will now be able to capitalize on MobileIron’s robust device management offering to complement Conditional Access by Microsoft. MobileIron will integrate with Microsoft Intune device compliance service to ensure only trusted and compliant devices have access to Microsoft 365 applications. Users must be licensed for Microsoft Intune and Azure Active Directory Premium, both included with Microsoft 365 E3 and Microsoft Enterprise Mobility + Security (EMS) E3 licensing bundles, in addition to appropriate MobileIron licenses.

“The workplace is evolving and becoming more mobile -- as a result, enterprise employees often turn to their mobile devices to handle critical work matters, which has serious security risks,” said Brian Foster, SVP of product management at MobileIron. “Enterprises can have peace of mind knowing that their devices have the security and protection they need when accessing Microsoft 365 applications in the cloud for a secure mobile work experience.”

This new integration expands upon MobileIron’s existing support for Microsoft Graph APIs for Intune, which currently allows joint customers to leverage Intune application protection policies for their Office 365 applications, while managing and securing the device with MobileIron. With these additional offerings, customers are able to marry Microsoft Enterprise Mobility + Security application protection and Conditional Access capabilities with MobileIron’s rich device management engine.

MobileIron is committed to providing an exceptional customer experience working with over 228 partners and offering integrated threat defense capabilities for an improved mobile security solution. This latest integration with Microsoft further confirms MobileIron’s mission to provide customers with more choice when it comes to securing Unified Endpoint Management. For more information, visit: www.mobileiron.com.

About MobileIron

MobileIron is redefining enterprise security with the industry’s first mobile-centric, zero trust platform built on the foundation of unified endpoint management (UEM) to secure access and protect data across the perimeter-less enterprise. Over 17,000 customers, including the world’s largest financial institutions, intelligence agencies, and other highly regulated companies rely on MobileIron to enable a seamless and secure user experience by ensuring only authorized users, devices, apps, and services can access business resources. For more information, visit www.mobileiron.com.

Statements in the press release concerning future product availability and plans are forward looking statements, and they are subject to change. They do not represent a commitment, promise or legal obligation to deliver any material, code or functionality, and should not be relied upon in making purchasing decision.

Contact information

Media contact:
Jenny Pfleiderer
press@mobileiron.com

Analyst contact:
Becca Chambers
bchambers@mobileiron.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ResMed Inc. Completes $500M Private Placement Debt Offering15.7.2019 20:05:00 CESTPress release

ResMed Inc. (NYSE: RMD, ASX: RMD) announced today the successful pricing and closing of a private placement offering of $250,000,000 principal amount 3.24% senior notes due July 10, 2026, and $250,000,000 principal amount 3.45% senior notes due July 10, 2029. Net proceeds from the offering will be approximately $498 million, after deducting estimated fees and expenses related to the offering. The net proceeds will be used to pay down current borrowings on ResMed’s senior unsecured revolving credit facility. The notes are senior unsecured obligations of ResMed, and jointly and severally guaranteed by each Subsidiary Guarantor. “We are pleased to complete this U.S. private placement offering on attractive terms,” said Brett Sandercock, ResMed’s chief financial officer. “The transaction significantly lengthens our average debt maturity profile and provides improved visibility on our long-term funding costs.” This private placement offering is exempt from the registration requirements of t

SpeeDx Receives Clearance from Health Canada for ResistancePlus® MG Test15.7.2019 15:00:00 CESTPress release

SpeeDx Pty. Ltd. today announced Resistance Plus® MG has been cleared by Health Canada and is now available for sale across all Canadian provinces (not currently available in the U.S.). The molecular diagnostic test detects the sexually transmitted infection (STI) Mycoplasma genitalium, also known as Mgen, along with genetic markers linked to antibiotic resistance. This is the first commercially available test in Canada combining identification and therapeutic guidance information to support Resistance Guided Therapy for management of Mgen. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190715005544/en/ (Photo: Business Wire) Current Canadian management guidelines for Mgen direct laboratories to forward positive samples to the National Microbiology Laboratory for resistance testing.1 Now Canadian laboratories can utilize Resistance Plus MG and bring this service inhouse to generate more timely results for doctors and their p

Mouser Electronics Now Stocking Broad Portfolio of Xilinx Products15.7.2019 14:55:00 CESTPress release

Mouser Electronics, Inc. today announces a new global distribution agreement with Xilinx, Inc., the leader in adaptive and intelligent computing, to stock one of the industry’s broadest portfolios of Xilinx products, including digital downloads of development software and IP. Xilinx is the inventor of the FPGA, hardware programmable system-on-chips (SoCs) and the adaptive compute acceleration platform (ACAP), designed to deliver the most dynamic processor technology in the industry and enable the adaptable, intelligent and connected world of the future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190715005546/en/ Mouser Electronics proudly announces a new global distribution agreement with Xilinx, Inc., the leader in adaptive and intelligent computing. Mouser will stock one of the industry’s broadest portfolios of Xilinx products. (Graphic: Business Wire) To learn more, visit www.mouser.com/xilinx. “Xilinx is an industry

Rimini Street Becomes Support Service Provider for Hyundai-Kia Motors’ Global Database Portfolio15.7.2019 13:00:00 CESTPress release

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that it has been selected as the software support services provider to global auto manufacturer Hyundai-Kia Motors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190715005161/en/ Rimini Street announced that it has been selected as the software support services provider to global auto manufacturer Hyundai-Kia Motors. (Photo: Business Wire) By providing efficient, timely, and cost-effective database maintenance and support, Rimini Street plans to actively support Hyundai-Kia Motors in their endeavor to implement a business-driven IT roadmap. Cost Optimization and Desire for Quality Support To support response to paradigm shifts in the automobile industry and active technology innovation, Hyundai-Kia Motors se

Värde Partners Appoints Co-CEO15.7.2019 12:12:00 CESTPress release

Värde Partners, a leading global alternative investment firm, today announced that Ilfryn Carstairs will join George Hicks, Co-Founder and Chief Executive Officer, as Co-CEO, effective January 1, 2020. George co-founded Värde Partners 25 years ago and intends to transition to an Executive Chair role in 2022. Ilfryn will retain his role as Global CIO. “Transition is a process and involves the entirety of the firm. The roles Ilfryn and I play are just part of that process whereby a new generation of leaders succeed the founders,” said George. “Ilfryn joined us 12 years into this journey and has grown as both an investor and a leader. His skills in both pursuits will enable Värde to continue delivering for our investors and will help to ensure that we maintain our strong culture long into the future.” Ilfryn is a Partner and Co-Chief Investment Officer overseeing the global investment strategy for Värde. He co-chairs the firm’s Investment Committee. Based in Singapore since 2017, he joine

Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform15.7.2019 12:00:00 CESTPress release

Boehringer Ingelheim today announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and advancing first-in-class therapeutic cancer vaccines derived from its technology platform KISIMA. AMAL’s lead vaccine ATP128 is currently developed for stage IV colorectal cancer and is slated to begin first-in-human trials later this month. Boehringer Ingelheim plans to develop new therapies by combining assets from its cancer immunology portfolio with AMAL’s proprietary KISIMA immunization platform. “Acquiring AMAL is part of Boehringer Ingelheim’s long-term strategy to enhance our existing position as an innovator of novel cancer therapies, including immuno-oncology treatments, which leverage cutting-edge scientific discoveries and their applications,” said Michel Pairet, member of Boehringer Ingelheim’s Board of Managing Directors with responsibility for the company’s Innovation Unit. “We want to pioneer new paradigms